TrialJournal of clinical pharmacology2017

Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.

Jing Niu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.